Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform technology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2007-07-10. The company specializes in stabilizing carbohydrate molecules. The company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two advanced programs are the cosmetic skin lightener and diabetes drug. Other projects include the development of an anti-aging / cell protection library, a novel anti-wrinkle compound, and the launch of an anti-viral program. Its TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. The company is focused on three antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its subsidiary is TFChem S.A.R.L.
Follow-Up Questions
Sirona Biochem Corp 的 CEO 是誰？
Dr. Howard Y 是 Sirona Biochem Corp 的 Chairman of the Board，自 2020 加入公司。
SRBCF 股票的價格表現如何？
SRBCF 的當前價格為 $0.0103，在上個交易日 decreased 了 0%。
Sirona Biochem Corp 的主要業務主題或行業是什麼？
Sirona Biochem Corp 屬於 Biotechnology 行業，該板塊是 Health Care
